NEOK002 not checked

NEOK Bio, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Main trialPhase 1
“This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).”In the company’s words, NCT07612189 on ClinicalTrials.gov

Other drugs for Locally Advanced (Unresectable) or Metastatic Solid Tumors

All 302 drugs for Locally Advanced (Unresectable) or Metastatic Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Feb 2029 A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow NEOK002

Following is part of Solo: you see every change to NEOK002 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in